EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX‐351) for the Treatment of Adults with Newly Diagnosed, Therapy‐Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia‐Related Changes

On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML). Vyxeos was designated as an orphan medicinal product o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Tzogani, Kyriaki, Penttilä, Karri, Lapveteläinen, Tuomo, Hemmings, Robert, Koenig, Janet, Freire, João, Márcia, Silva, Cole, Susan, Coppola, Paola, Flores, Beatriz, Barbachano, Yolanda, Roige, Silvia Domingo, Pignatti, Francesco
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Regulatory Issues: EMA
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485353/
https://ncbi.nlm.nih.gov/pubmed/32282100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0785
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares